ANDA 209750, held by Apotex. Atovaquone.
As of Nov 21, 2026, ANDA 209750 (Atovaquone), held by Apotex, was first approved by FDA on Oct 11, 2017, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 11, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Atovaquone750MG/5ML · suspension;oral | Atovaquone | Discontinued |
| Sep 23, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 20, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 20, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 21, 2018 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 11, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters